AVEO prices IPO; misses target range
12 March 2010
Simon Varcoe
Please Login to read the full article.
12 March 2010
Simon Varcoe
simon.varcoe@informa.com
AVEO Pharmaceuticals has finally launched its IPO, after delaying the pricing by a day.
The cancer-focused biopharmaceutical company priced 9 million shares of its common stock at $9 per share after Nasdaq closed on March 11th. However, AVEO had hoped to reap as much as $105...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Cancer developer Merrimack dives into a tough IPO pool with a $172M filing
- Affymax $50M offering, as Hematide still on track for Q2 US filing
- Synageva makes public spectacle with $60 million stock offer after Trimeris merger
- Weaker private equity in India for 2012, portfolios turning 'a la carte'
COMMENT
Other Informa Comment
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
